Clinical Trial Update: BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Paroxetine Hydrochloride Hydrate (BRL29060A) for Post-Traumatic Stress Disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• Paroxetine Hydrochloride Hydrate (BRL29060A) (Paroxetine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Post-Traumatic Stress Disorder | Phase 3 | Status: COMPLETED